|
|
Vaccine Detail
|
12MP |
| Vaccine Information |
- Vaccine Name: 12MP
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007189
- Type: Subunit vaccine
- Status: Research
- Immunization Route: Intramuscular injection (i.m.)
- Description: 12MP is a melonoma vaccine that uses 12 class I MHC–restricted melanoma peptides from cancer-testis antigens (CTAs) and melanocytic differentiation proteins (MDPs) (Slingluff et al., 2011; Slingluff et al., 2013)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: The vaccine comprised of 12 melanoma peptides from MDP and CTA restricted by HLA-A1, A2, or A3, to stimulate CTL. Vaccination with 12MP plus tetanus induced CD8(+) T-cell responses in 78% of patients and CD4(+) T-cell responses to tetanus peptide in 93% of patients. Vaccination with 12MP plus 6MHP induced CD8(+) responses in 19% of patients and CD4(+) responses to 6MHP in 48% of patients. CY had no significant effect on T-cell responses (Slingluff et al., 2011; Slingluff et al., 2013)
|
| References |
Slingluff et al., 2011: Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29(21); 2924-2932. [PubMed: 21690475].
Slingluff et al., 2013: Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(15); 4228-4238. [PubMed: 23653149].
|
|
